Biersack Bernhard
Organic Chemistry Laboratory, University of Bayreuth, Universitätsstraße 30, 95447, Bayreuth, Germany.
Noncoding RNA Res. 2018 Nov 4;3(4):213-225. doi: 10.1016/j.ncrna.2018.11.001. eCollection 2018 Dec.
Gemcitabine and pemetrexed are clinically approved antimetabolites for the therapy of mesothelioma diseases. These drugs are often applied in combination with platinum complexes and other drugs. The activity of antimetabolites depended on the expression levels of certain non-coding RNAs, in particular, of small microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). The development of tumor resistance towards antimetabolites was regulated by non-coding RNAs. An overview of the interplay between gemcitabine/pemetrexed antimetabolites and non-coding RNAs in mesothelioma is provided. Further to this, various non-coding RNA-modulating agents are discussed which displayed positive effects on gemcitabine or pemetrexed treatment of mesothelioma diseases. A detailed knowledge of the connections of non-coding RNAs with antimetabolites will be constructive for the design of improved therapies in future.
吉西他滨和培美曲塞是临床上批准用于治疗间皮瘤疾病的抗代谢药物。这些药物常与铂类复合物及其他药物联合使用。抗代谢药物的活性取决于某些非编码RNA的表达水平，特别是小的微小RNA（miRNA）和长链非编码RNA（lncRNA）。肿瘤对抗代谢药物的耐药性发展受非编码RNA调控。本文概述了吉西他滨/培美曲塞抗代谢药物与间皮瘤中非编码RNA之间的相互作用。此外，还讨论了各种对吉西他滨或培美曲塞治疗间皮瘤疾病显示出积极作用的非编码RNA调节剂。深入了解非编码RNA与抗代谢药物之间的联系将有助于未来设计出更优的治疗方案。
Zotero 插件
